Quizartinib Disease Interactions

Quizartinib prolongs the QT interval in a dose and concentration dependent manner. Due to the serious risk of QTc prolongation, quizartinib is contraindicated in patients with long QT syndrome, a history of ventricular arrhythmias or torsades de points, severe hypokalemia, or severe hypomagnesemia. Additionally, avoid use in patients who are at significant risk of developing torsades de pointes, including uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, tachyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Perform an ECG and correct electrolyte abnormalities before and during treatment as indicated, especially in high-risk patients or during concomitant use with strong CYP450 3A4 inhibitors or drugs known to prolong the QT interval. Do not initiate or escalate therapy in patients with QTcF interval greater than 450 ms; dose adjustments based on QTcF interval may be required.

Midostaurin and quizartinib should be used with caution in patients with severe hepatic or severe renal dysfunction as the pharmacokinetics of these agents have not been studied in these patients. No dosage adjustments are recommended in patients with mild or moderate hepatic or renal dysfunction.